Work in progress to be organized.

From the drug label regarding patient counseling, this is all doctors are told to advise their patients:

17 PATIENT COUNSELING INFORMATION

Loss of Bone DensityAdvise patients about the risk of loss of bone mineral density and that treatment is limited [see Dosage and Administration ( 2.1 ) ]. Advise patients about other factors that can increase and decrease their risk of bone mineral density loss [see Warnings and Precautions ( 5.1 ) ].

Embryo-Fetal Toxicity

Advise females of reproductive potential of the possible risk to a fetus. Advise patients to inform healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.2 ) and Use in Special Populations ( 8.1 ) ].

If contraception is indicated, advise females of reproductive potential to use non-hormonal contraception during treatment with LUPRON DEPOT 3.75 mg [see Use in Special Populations ( 8.3 ) ].

Severe Cutaneous Adverse Reactions

Inform patients that severe cutaneous adverse reactions (SCARs) may occur during treatment with LUPRON DEPOT 3.75 mg. Advise patients to discontinue LUPRON DEPOT 3.75 mg and immediately contact their healthcare provider if they experience signs or symptoms of SCARs [ see Warnings and Precautions ( 5.3 ) ].

Hypersensitivity Reactions

Inform patients that hypersensitivity reactions, including anaphylaxis, have been reported with LUPRON DEPOT. Advise patients to seek appropriate medical care if symptoms of hypersensitivity reactions occur [see Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 ) ].

Initial Flare of Symptoms

Advise patients that they may experience an increase in symptoms during the initial days of therapy. Advise patients that these symptoms should dissipate with continued therapy [see Warnings and Precautions ( 5.5 ) ].

Convulsions

Inform patients that convulsions have been reported in patients who have received LUPRON DEPOT. Advise patients to seek medical attention in the event of a convulsion [see Warnings and Precautions ( 5.6 ) ].

Clinical Depression

Inform patients that depression may occur or worsen during treatment with GnRH agonists, including LUPRON DEPOT 3.75 mg, especially in patients with a history of depression. Advise patients to immediately report thoughts and behaviors of concern to healthcare providers [see Warnings and Precautions ( 5.7 ) ].

Manufactured for
AbbVie Inc.
North Chicago, IL 60064
by Takeda Pharmaceutical Company Limited
Osaka, Japan 540-8645 Revised 09/202520085416

That’s all the information parents and their children are getting from doctors about Lupron.

This information was obtained from the drug’s label as found in the National Library of Medicine’s DailyMed database.
Please refer to the complete label here Official Drug Label for LUPRON DEPOT.

784 LUPRON DEPOT Reviews
https://www.askapatient.com/viewrating.asp?drug=19732&name=LUPRON+DEPOT

854 LUPRON Reviews (LEUPROLIDE ACETATE)
https://www.askapatient.com/viewrating.asp?drug=19010&name=LUPRON

4 LUPRON DEPOT-PED Reviews (LEUPROLIDE ACETATE)
https://www.askapatient.com/viewrating.asp?drug=20263&name=LUPRON+DEPOT%2DPED

110 LUPRON DEPOT-3 Reviews (LEUPROLIDE ACETATE)
https://www.askapatient.com/viewrating.asp?drug=20708&name=LUPRON+DEPOT%2D3

Adverse event summary for Lupron (Death is #3):
https://www.askapatient.com/adverse-events.asp?drug=LUPRON+DEPOT

291 ZOLADEX Reviews (GOSERELIN ACETATE)
https://www.askapatient.com/viewrating.asp?drug=19726&name=ZOLADEX

Adverse event summary for Zoladex (Death is #1):
https://www.askapatient.com/adverse-events.asp?drug=ZOLADEX

Zoladex adverse events death — Death is the top reported adverse event

Source:
https://www.askapatient.com/adverse-events.asp?drug=ZOLADEX

PDF File:

14 SYNAREL Reviews (NAFARELIN ACETATE)
https://www.askapatient.com/viewrating.asp?drug=19886&name=SYNAREL

Drug Safety Information for LUPRON (Leuprolide acetate)

5/19/2017 & 12/10/2018 Safety-related Labeling Changes for LUPRON (LEUPROLIDE ACETATE) Rx Drug: FDA Link

6/6/2016, 12/10/2018, & 6/6/2016 Safety-related Labeling Changes for LUPRON DEPOT (LEUPROLIDE ACETATE) Rx Drug: FDA Lin

5/19/2017 & 4/7/2020 Safety-related Labeling Changes for LUPRON DEPOT-PED (LEUPROLIDE ACETATE) Rx Drug: FDA Link

6/6/2016, 12/10/2018, & 3/4/2019 Safety-related Labeling Changes for LUPRON DEPOT (LEUPROLIDE ACETATE) Rx Drug: FDA Link

4/18/2018 & 3/18/2020 Safety-related Labeling Changes for LUPRON DEPOT (LEUPROLIDE ACETATE) Rx Drug: FDA Link

2/15/2019 Safety-related Labeling Changes for ELIGARD (LEUPROLIDE ACETATE) Rx Drug: FDA Link

Note:

Pituitary apoplexy-During post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.